Zimbabwe has declined a major American health deal worth $367m (£272m) over five years due to Washington's request for sensitive data.
This rejection came to light after a internal memorandum from December was disclosed, revealing that Head of State Emmerson Mnangagwa believed the arrangement was "unbalanced".
A government spokesman has since explained that the United States was demanding access to biological samples for research and commercial gain while was not willing to share the resulting advantages from future treatments.
"We are forced to start the challenging and unfortunate process of winding down our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had furnished more than $1.9bn for health programmes to Zimbabwe over the last two decades.
A medical body in Zimbabwe has urged continued dialogue to find a deal suitable to both sides so the nation's critical HIV treatment initiative can proceed.
Wider Implications
Zimbabwe's decision comes after a comparable situation in neighbouring Kenya, where a court halted a similar deal with the US after legal challenges were raised about the security of Kenyans' medical information.
After resuming office recently, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
The agency had administered aid for the American government, but Trump stated its spending was "inefficient" and his government was pursuing government-to-government deals to enhance openness and accountability.
According to reports, Sixteen African countries have to date agreed to these new agreements, constituting more than $18.3bn in committed funds.
Details of the Declined Deal
This assistance for Zimbabwe would have supported "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this collaboration could have provided significant advantages for Zimbabwean communities, particularly the 1.2 million presently receiving HIV treatment via US-supported programmes," Tremont commented.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"The proposal required Zimbabwe to provide its genetic material and health information for a long time, with no corresponding promise of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could be developed from that shared data," Mangwana explained.
"In essence, our nation would provide the raw materials for medical research with no certainty that the final treatments would be available to our population if a new pandemic emerge."
National Interest and Global Health
He also noted that the US's withdrawal from the global health body and its push of bilateral deals were undermining structures already set up via the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing system designed to deal with potential global health emergencies.
"This framework is intended to guarantee that when a country provides its information, the benefits – such as medicines and cures – are distributed fairly, not commercialised solely by those with the resources to create them."
These objections regarding the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We are open to ongoing discussions with our US partners on how subsequent co-operation could be structured in a manner that respects the sovereignty and interests of each country."
Medical Community Response
Medical experts said it understood the government's concerns, but urged that negotiations need to persist since a large portion of the country's Aids initiatives relied on international support.
"If specific concerns arise, including those relating to data governance or agreement terms, these can often be addressed via technical clarification and negotiated safeguards," it said.
The situation highlights the complex debate between receiving vital foreign assistance and safeguarding national sovereignty in an ever more data-driven world.